MedTrace Logo

COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study

NCT04385069 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-05-12

No results posted yet for this study

Summary

Based on emerging experience and trials from countries affected early by the COVID-19 (COV19) pandemic, there is evidence that a subgroup of severely affected people develop a hyperinflammatory (HI) syndrome (COV-HI). Trials are in progress of cytokine inhibition and other immune modulation to treat COV-HI. This proposal aims to use a rapidly executed cohort study to characterise the clinical phenotypes of COV-HI in patients in the UK through an established and nimble network of clinicians and scientists with broad experience of identifying and treating HI. The aim is to confirm the COV-HI clinical phenotype and using routine data to try to infer the inflexion point where COV-HI emerges. This would enable refinement of the proposed treatment algorithm and translates to routine clinical practice to improve the outlook for COV-HI.

Conditions

  • COV-HI
  • COVID-19
  • COVID-19 (COV) Hyperinflammatory (HI) Syndrome

Sponsors & Collaborators

  • Newcastle-upon-Tyne Hospitals NHS Trust

    collaborator OTHER

  • Sheffield Teaching Hospitals NHS Foundation Trust

    collaborator OTHER

  • The Leeds Teaching Hospitals NHS Trust

    collaborator OTHER

  • Nottingham University Hospitals NHS Trust

    collaborator OTHER

  • University College London Hospitals

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • Jessica Manson, Dr · University College London Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-16
Primary Completion
2020-07-05
Completion
2020-07-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04385069 on ClinicalTrials.gov